Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacek Bil

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Cardiology Journal|June 4, 2024
Clinical characteristics and predictors of in-hospital mortality of patients hospitalized with myocardial infarction before and during COVID-19 pandemicAdam Kern, Sebastian Pawlak, Grzegorz Poskrobko, et al.
Kardiologia Polska|August 4, 2022
When an interventional cardiologist needs an interventional radiologist: Efficient treating of coronary perforationAdam Kern, Robert Gil, Grzegorz Wasilewski, et al.
Cancer Letters|October 14, 2009
Photodynamic therapy-driven induction of suicide cytosine deaminase geneJacek Bil, Pawel Wlodarski, Magdalena Winiarska, et al.
The Canadian Journal of Cardiology|April 2, 2015
Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I TrialRobert J Gil, Jacek Bil, Vladimír Džavík, et al.
Journal of Personalized Medicine|January 22, 2024
Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic StrokeRakesh Jalali, Jacek Zwiernik, Ewa Rotkiewicz, et al.
Cardiovascular Therapeutics|May 16, 2020
Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II StudiesRobert J Gil, Jacek Bil, Adam Kern, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 10, 2018
Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS stents for coronary bifurcation treatment: four-year results of the randomised POLBOS I and POLBOS II clinical trialsRobert J Gil, Jacek Bil, Adam Kern, et al.
Clinical Medicine Insights. Cardiology|November 16, 2020
Carcinoid Heart Disease: How to Diagnose and Treat in 2020?Barbara Bober, Marek Saracyn, Maciej Kołodziej, et al.
Polish Archives of Internal Medicine|January 5, 2023
Clinical characteristics and 12-month outcomes of patients with myocardial infarction with nonobstructive coronary arteries before and during the COVID-19 pandemicJacek Bil, Adam Kern, Kamil Bujak, et al.
Cardiology Journal|August 26, 2017
Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studiesRobert J Gil, Jacek Bil, Adam Kern, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Cardiology Journal|June 4, 2024
Clinical characteristics and predictors of in-hospital mortality of patients hospitalized with myocardial infarction before and during COVID-19 pandemicAdam Kern, Sebastian Pawlak, Grzegorz Poskrobko, et al.
Kardiologia Polska|August 4, 2022
When an interventional cardiologist needs an interventional radiologist: Efficient treating of coronary perforationAdam Kern, Robert Gil, Grzegorz Wasilewski, et al.
Cancer Letters|October 14, 2009
Photodynamic therapy-driven induction of suicide cytosine deaminase geneJacek Bil, Pawel Wlodarski, Magdalena Winiarska, et al.
The Canadian Journal of Cardiology|April 2, 2015
Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I TrialRobert J Gil, Jacek Bil, Vladimír Džavík, et al.
Journal of Personalized Medicine|January 22, 2024
Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic StrokeRakesh Jalali, Jacek Zwiernik, Ewa Rotkiewicz, et al.
Cardiovascular Therapeutics|May 16, 2020
Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II StudiesRobert J Gil, Jacek Bil, Adam Kern, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 10, 2018
Regular drug-eluting stents versus dedicated bifurcation drug-eluting BiOSS stents for coronary bifurcation treatment: four-year results of the randomised POLBOS I and POLBOS II clinical trialsRobert J Gil, Jacek Bil, Adam Kern, et al.
Clinical Medicine Insights. Cardiology|November 16, 2020
Carcinoid Heart Disease: How to Diagnose and Treat in 2020?Barbara Bober, Marek Saracyn, Maciej Kołodziej, et al.
Polish Archives of Internal Medicine|January 5, 2023
Clinical characteristics and 12-month outcomes of patients with myocardial infarction with nonobstructive coronary arteries before and during the COVID-19 pandemicJacek Bil, Adam Kern, Kamil Bujak, et al.
Cardiology Journal|August 26, 2017
Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studiesRobert J Gil, Jacek Bil, Adam Kern, et al.
Pageof 13